⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TBPH News
Theravance Biopharma, Inc.
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
prnewswire.com
TBPH
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
prnewswire.com
TBPH